Who are CT-P6's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SB5, Adalimumab and its biosimilars, Humira® (Adalimumab), Adalimumab treatment arm, Adalimumab Ab, Golimumab (GLM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ct-p6.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CT-P6 — Competitive Intelligence Brief

CT-P6 (CT-P6) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody); infliximab biosimilar. Area: Immunology / Rheumatology / Gastroenterology.

phase 3 TNF-α inhibitor (monoclonal antibody); infliximab biosimilar TNF-α (tumor necrosis factor alpha) Immunology / Rheumatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

CT-P6 (CT-P6) — Celltrion. CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CT-P6 TARGET	CT-P6	Celltrion	phase 3	TNF-α inhibitor (monoclonal antibody); infliximab biosimilar	TNF-α (tumor necrosis factor alpha)
SB5	SB5	Samsung Bioepis Co., Ltd.	marketed	TNF-α inhibitor (monoclonal antibody); biosimilar	TNF-α (tumor necrosis factor-alpha)
Adalimumab and its biosimilars	Adalimumab and its biosimilars	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Humira® (Adalimumab)	Humira® (Adalimumab)	Mylan Inc.	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Adalimumab treatment arm	Adalimumab treatment arm	Medical University of Vienna	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab Ab	Adalimumab Ab	Qilu Hospital of Shandong University	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Golimumab (GLM)	Golimumab (GLM)	University College Dublin	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody); infliximab biosimilar class)

Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P6 — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p6. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab